Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Working Capital Changes: 2023-2025

Historic Other Working Capital Changes for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $110.2 million.

  • Monte Rosa Therapeutics' Other Working Capital Changes rose 1295.92% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 172.32%. This contributed to the annual value of $83.4 million for FY2024, which is 66.76% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Other Working Capital Changes stood at $110.2 million, which was up 579.83% from -$23.0 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Other Working Capital Changes high stood at $110.2 million for Q3 2025, and its period low was -$83.9 million during Q1 2025.
  • For the 3-year period, Monte Rosa Therapeutics' Other Working Capital Changes averaged around $12.4 million, with its median value being $2.3 million (2024).
  • Data for Monte Rosa Therapeutics' Other Working Capital Changes shows a peak YoY increase of 1,295.92% (in 2025) and a maximum YoY decrease of 3,770.31% (in 2025) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Other Working Capital Changes (Quarterly) stood at $40.0 million in 2023, then skyrocketed by 123.38% to $89.4 million in 2024, then surged by 1,295.92% to $110.2 million in 2025.
  • Its last three reported values are $110.2 million in Q3 2025, -$23.0 million for Q2 2025, and -$83.9 million during Q1 2025.